Physician profile
Juan E Rubio
NPI 1639148711
$5,372.00
in general payments reported to CMS, 2019-2025
19 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $200 · 2021: $516 · 2022: $605 · 2023: $738 · 2024: $812 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,248.29 | 2019-2021 | |
| Genentech USA, INC. | $882.68 | 2021-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $508.37 | 2022-2025 | Syfovre |
| Abbvie INC. | $397.29 | 2022-2025 | Ozurdex |
| Mallinckrodt Hospital Products INC. | $293.33 | 2023-2025 | Acthar |
| Alcon Vision LLC | $288.86 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $263.59 | 2022-2025 | Eylea Hd |
| Harrow Eye, LLC | $257.85 | 2023-2025 | Triesence, Iheezo |
| Allergan, INC. | $243.48 | 2019-2021 | |
| Eyepoint US, INC. | $229.56 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $193.67 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Takeda Pharmaceuticals U.S.A., INC. | $147.86 | 2024-2025 | Cuvitru |
| Mallinckrodt Enterprises LLC | $132.75 | 2019 | |
| Dutch Ophthalmic, USA | $101.25 | 2019 | |
| Astellas Pharma US INC | $94.12 | 2023-2025 | Izervay |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $34.67 | 2020-2021 | |
| Alimera Sciences, INC. | $34.63 | 2019-2024 | Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $19.75 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Rubio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.